Johnson & Johnson reports sustained psoriasis skin clearance
Share
Johnson & Johnson (NYSE:JNJ) announced Phase 3 clinical results showing sustained skin clearance with ICOTYDE for plaque psoriasis.
Johnson & Johnson (NYSE:JNJ) announced Phase 3 clinical results showing sustained skin clearance with ICOTYDE for plaque psoriasis.
Johnson & Johnson (NYSE:JNJ) offered $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and other talc products caused ovarian cancer.
Johnson & Johnson (NYSE:JNJ) secured FDA De Novo authorization for its four-arm OTTAVA robotic surgical system.
Johnson & Johnson (NYSE:JNJ) reported five-year CARTITUDE-2 study results showing that 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy after receiving a single infusion.
Johnson & Johnson (NYSE:JNJ) reported two-year findings for IMAAVY in adolescents with generalized myasthenia gravis (gMG), along with results from a retrospective survey evaluating adults who switched to the therapy from other advanced treatments.
